Author |
N |
Method |
Treatment |
Endpoint |
Comment |
Giralt |
87 |
IHC |
45-50.4 Gy
+/- 5-
FU+LV o
UFT+LV |
pCR;DFS/OS;Metastasis-free survival |
EGFR expression associated with decreased pCR rate |
Kim |
183 |
IHC |
50 Gy 5-
FU+LV |
TRG; TNM downstaging |
Low EGFR expression associated with TNM downstaging |
Spindler |
77 |
PCR/DNA |
65 Gy
UFT+LV |
TRG |
EGFR Sp1-216 associated with tumor response |
Spindler |
60 |
PCR/DNA |
65 Gy
UFT+LV |
TRG |
Combination of TS 2R/2R and EGFR 61A/G or EGFR Sp1-216T associated with tumor regresión |
Bertolini |
91 |
IHC |
50 Gy 5-FU |
TRG; TNM downstaginf;DFS/OS |
No correlation |
Toiyama |
40 |
PCR/RNA |
20 Gy 5-
FU+UFT |
TNM downstaging |
Low EGFR expression associated with high response rate |
Bengala |
39 |
IHC;FISH;
PCR/DNA |
50.4 Gy 5-
FU+Cetuximab |
TRG |
High EGFR and wild-type KRAS associated with response to treatment |
Debucquoy |
41 |
IHC |
50.4 Gy 5-
FU+LV |
TRG; TNM downstaging |
No correlation |
Bengala |
146 |
IHC;FISH;PCR/DNA |
50 Gy 5-
FU+/-Oxa+Capecitabine |
TRG;DFS/OS |
No association of EGFR, GCN and KRAS with TRG and OS |
EGFR: epidermal growth factor receptor; ICH: imunohistochemistry; PCR: polymerase chain reaction; FISH: fluorescence in situ hybridization; 5-FU: 5-floruracil; LV: leucovorin; Oxa: oxaliplatin; UFT: Uftoral; pCR: complete pathological response; DFS: disease-free survival; OS: overall survival; TRG: tumor regression grade; TNM: tumor node metastasis staging; TS: thymidylate synthase; EGF: epidermal growth factor; EGFR GCN: EGFR gene copy number. |
